Expression, purification, characterization and crystallization of non- and phosphorylated states of JAK2 and JAK3 kinase domain

Protein Expression and Purification

Volumn 69, Issue 1, 2010, Pages 54-63

  Hall, Troii ^a   Emmons, Thomas L ^a   Chrencik, Jill E ^a   Gormley, Jennifer A ^a   Weinberg, Robin A ^a   Leone, Joseph W ^a   Hirsch, Jeffrey L ^a   Saabye, Matthew J ^a   Schindler, John F ^a   Day, Jacqueline E ^a   Williams, Jennifer M ^a   Kiefer, James R ^a   Lightle, Sandra A ^a   Harris, Melissa S ^a   Guru, Siradanahalli ^a   Fischer, H David ^a   Tomasselli, Alfredo G ^a  

^a PFIZER INC   (United States)

Author keywords

Assay development; JAK2; JAK3; Non receptor protein tyrosine kinase; Phosphorylation states; Protein purification

Indexed keywords

JANUS KINASE 2; JANUS KINASE 3;

AMINO ACID SEQUENCE; ARTICLE; BIOCATALYSIS; CHEMISTRY; CRYSTALLIZATION; FERMENTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ISOLATION AND PURIFICATION; KINETICS; MOLECULAR GENETICS; PHOSPHORYLATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN TERTIARY STRUCTURE;

AMINO ACID SEQUENCE; BIOCATALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRYSTALLIZATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FERMENTATION; HUMANS; JANUS KINASE 2; JANUS KINASE 3; KINETICS; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY;

EID: 70350572308     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2009.09.011     Document Type: Article

References (29)

1. Shuai K., and Liu B. Regulation of JAK-STAT signaling in the immune system. Nat. Rev. Immunol. 3 (2003) 900-911
2. Levy D., and Darnell Jr. J. STATs: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 3 (2002) 651-662
3. O'Shea J. JAKs, STATs, cytokine signal transduction, and immuno-regulation: are we there yet?. Immunity 7 (1997) 1-11
4. Reddy E., Korapati A., Chaturvedi P., and Rane S. IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled. Oncogene 19 (2000) 2532-2547
5. Fischer A. Human primary immunodeficiency diseases. Immunity 27 (2007) 835-845
6. Macchi P., Villa S., Giliani M., Sacco A., Frattini F., Porta A., Ugazio J., Johnston F., Candotti J., O'Shea J., et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377 (1995) 65-68
7. Bernasconi A., Marino R., Ribas A., Rossi J., Ciaccio M., Oleastro M., Ornani A., Paz R., Rivarola M.A., Zelazko M., and Belgorosky A. Characterization of immunodeficiency in a patient with growth hormone insensitivity secondary to a novel STAT5b gene mutation. Pediatrics 118 (2006) 1584-1592
8. O'Shea J., Husa M., Li D., Hofmann S., Watford W., Roberts J., Buckley R., Changelian P., and Candotti F. Jak3 and the pathogenesis of severe combined immunodeficiency. Mol. Immunol. 41 (2004) 727-737
9. Nosaka T., van Deursen J., Tripp R., Thierfelder W., Witthuhn B., McMickle A., Doherty P., Grosveld G., and Ihle J. Defective lymphoid development in mice lacking JAK3. Science 270 (1995) 800-802
10. Papageorgiou A., and Wikman L. Is JAK3 a new drug target for immunomodulation-based therapies?. Trends Pharmacol. Sci. 25 (2004) 558-562
11. Neubauer H., Cumano A., Muller M., Wu H., Huffstadt U., and Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93 (1998) 397-409
12. Parganas E., Wang D., Stravopodis D., Topham D., Marine J., Teglund S., Vanin E., Bodner S., Colamonici O., van Deusen J., Grosveld G., and Ihle J. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93 (1998) 385-395
13. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 22 (2008) 23-30
14. J. Silverfield et al., CP-690,550, an Oral JAK inhibitor, is a well-tolerated and effective long-term treatment for patients with moderate to severe RA, in: ACR/ARHP Annual Scientific Meeting, San Francisco, USA, October 2008, Presentation 1189.
15. Busque S., Leventhal J., Brennan D., et al. CP-690, 550 (CP), a JAK3 inhibitor, in de novo kidney transplant (KT) recipients: 6-month results of a phase 2 trial. Am. J. Transplant. 2 (2007) 304
16. Morgan K., and Gilliland D. A role for JAK2 mutations in myeloproliferative diseases. Annu. Rev. Med. 59 (2008) 213-222
17. Duhe R., Clark E., and Farrar W. Characterization of the in vitro kinase activity of a partially purified soluble GST/JAK2 fusion protein. Mol. Cell. Biochem. 236 (2002) 23-35
18. Chatti K., Farrar W., and Duhe R. Tyrosine phosphorylation of the Janus Kinase 2 activation loop is essential for a high activity catalytic state but dispensable for a basal catalytic state. Biochemistry 43 (2004) 4272-4283
19. Feng J., Witthuhn B., Matsuda T., Koklhuber F., Kerr I., and Ihle J. Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol. Cell. Biol. 17 (1997) 2497-2501
20. Duhe R., and Farrar W. Characterization of active and inactive forms of the JAK2 protein-tyrosine kinase produced via the baculovirus expression vector system. J. Biol. Chem. 270 (1995) 23084-23089
21. Zhou Y., Hanson E., Chen Y., Magnuson K., Chen M., Swann P., Wange R., Changelian P., and O'Shea J. Distinct tyrosine phosphorylation sites in JAK3 kinase domain positively and negatively regulate its enzymatic activity. Proc. Natl. Acad. Sci. USA 94 (1997) 13850-13855
22. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., and Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289 (2000) 1938-1942
23. Wang R., Griffin P., Small E., and Thompson J. Mechanism of Janus Kinase 3-catalyzed phosphorylation of a Janus Kinase 1 activation loop peptide. Arch. Biochem. Biophys. 410 (2003) 7-15
24. Saltzman A., Stone M., Franks C., Searfoss G., Munro R., Jaye M., and Ivashchenko Y. Cloning and characterization of human Jak-2 kinase: high mRNA expression in immune cells and muscle tissue. Biochem. Biophys. Res. Commun. 246 (1998) 627-633
25. Olsen H., Faulds M.H., Saharinen P., Silvennoinen O., and Haldosen L. Effects of hyperactive JAK2 signaling in mammary epithelial cells. Biochem. Biophys. Res. Commun. 296 (2002) 139-144
26. Saharinen P., Vihinen M., and Silvennoinen O. Autoinhibition of JAK2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol. Cell. Biol. 14 (2003) 1448-1459
27. Boggon R., Li Y., Manley P., and Eck M. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood 106 (2005) 996-1002
28. Lucet I., Fantino E., Styles M., Bamert R., Patel O., Broughton S., Walter M., Burns C., Treutlein H., Wilks A., and Rossjohn J. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-janus kinase inhibitor. Blood 107 (2006) 176-183
29. Williams N., Bamert R., Patel O., Wang C., Walden P., Fantino E., Rossjohn J., and Lucet I. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domain. J. Mol. Biol. 387 (2009) 219-232